Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.

Nature chemical biology - 1 Sept 2016

Hohmann Anja F, Martin Laetitia J, Minder Jessica L, Roe Jae-Seok, Shi Junwei, Steurer Steffen, Bader Gerd, McConnell Darryl, Pearson Mark, Gerstberger Thomas, Gottschamel Teresa, Thompson Diane, Suzuki Yutaka, Koegl Manfred, Vakoc Christopher R

Abstract excerpt

Here we show that acute myeloid leukemia (AML) cells require the BRD9 subunit of the SWI-SNF chromatin-remodeling complex to sustain MYC transcription, rapid cell proliferation and a block in differentiation. Based on these observations, we derived small-molecule inhibitors of the BRD9 bromodomain that selectively suppress the proliferation of mouse and human AML cell lines. To establish these effects as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to Drug Screening Assays, Antitumor

Share to Leukemia, Myeloid, Acute

Share to Molecular Structure

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 27376689
DOI: 10.1038/nchembio.2115
PMCID: PMC4990482

Genes

BRD9
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.PMID 27376689Read ↗

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid LeukemiaSemantic proximity Read ↗

Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo StudiesSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemiaSemantic proximity Read ↗

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AMLSemantic proximity Read ↗

Bromodomains as therapeutic targets in cancerSemantic proximity Read ↗

The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9Semantic proximity Read ↗

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapySemantic proximity Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy StrategySemantic proximity Read ↗

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical ApplicationsSemantic proximity Read ↗

Targeting MYC dependence in cancer by inhibiting BET bromodomainsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.